Table S1.
Characteristics of study participants in the subset of data that were used to assess dyspnea and any symptoms as 34 participants were unable to walk due to a condition other than shortness of breath
| Visit 1 (n=347) | Visit 2 (n=241) | Visit 3 (n=268) | |
|---|---|---|---|
| Age | 65.0 (10.2) | 66.7 (9.8) | 67.9 (9.4) |
| Male (vs female) | 54.5% | 54.4% | 54.1% |
| BMI | 27.0 (4.9) | 27.1 (4.9) | 27.0 (4.9) |
| Caucasian (vs non-Caucasian) | 97.1% | 97.1% | 97.8% |
| Comorbiditiesa | |||
| 0 comorbidities | 62.8% | 56.4% | 57.1% |
| 1 comorbidity | 30.5% | 33.2% | 24.3% |
| ≥2 comorbidities | 6.6% | 10.4% | 18.7% |
| Anxiety/depression (vs no) | 18.2% | 19.5% | 19.4% |
| Smoking between visits (vs no) | 74.1% | 25.7% | 24.6% |
| Lifetime pack-years smoked | 26.2 (25.8) | 24.7 (25.4) | 26.3 (25.6) |
| Any exacerbationsb (vs no) | 7.5% | 10.0% | 14.6% |
| MPRc | 76.9% (107.6) | 75.7% (111.9) | 76.5% (107.7) |
| FEV1 (L) | 2.2 (0.8) | 2.1 (0.8) | 2.1 (0.7) |
| % Predicted FEV1 | 75.0 (17.8) | 76.1 (19.0) | 77.1 (18.5) |
| Diagnosed COPD (vs undiagnosed) | 23.3% | 27.0% | 32.5% |
| Asthma (vs no) | 21.0% | 26.6% | 29.9% |
| Symptoms (present vs absent) | |||
| Dyspnea | 53.3% | 46.5% | 44.8% |
| Any symptoms | 83.9% | 77.2% | 74.6% |
Notes: Means (SDs) are reported unless otherwise indicated.
a
Participants reported whether they had ever been diagnosed with coronary artery disease, hypertension, diabetes, lung cancer, stroke, and tuberculosis at each study visit.
b
COPD exacerbations of any severity (mild, moderate, severe) over the past 12 months.
c
12-month medication possession ratio for all respiratory-related medications.
Abbreviations: BMI, body mass index; MPR, medication possession ratio.